Etretinate
From Wikipedia, the free encyclopedia
 |
|
|
Etretinate
|
|
| Systematic (IUPAC) name | |
| ethyl 9-(4-methoxy-2,3,6-trimethyl-phenyl)- 3,7-dimethyl-nona- 2,4,6,8-tetraenoate | |
| Identifiers | |
| CAS number | |
| ATC code | D05 |
| PubChem | |
| DrugBank | |
| Chemical data | |
| Formula | C23H30O3 |
| Mol. mass | 354.483 g/mol |
| Pharmacokinetic data | |
| Bioavailability | ? |
| Metabolism | ? |
| Half life | 120 days |
| Excretion | ? |
| Therapeutic considerations | |
| Pregnancy cat. |
? |
| Legal status | |
| Routes | Oral |
Etretinate (trade name Tigason) is a medication used to treat severe psoriasis. It was removed from the United States market in 1998 and the Canadian market in 1996, due to the high risk of birth defects.
Etretinate has been replaced by acitretin, a metabolite of etretinate.
[edit] Precautions
- Etretinate is a teratogen, and may cause birth defects long after use. Therefore, etretinate should only be used if one is never to get pregnant.
- Etretinate should be avoided in children, as it may interfere with growth of bone.
[edit] Side effects
|
||||||||||||||||||||
 |
This pharmacology-related article is a stub. You can help Wikipedia by expanding it. |
